Get started
Work

Abstract PO5-19-08: Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP): An Open Label Randomized Phase II Trial

Year: 2024
Type: conference-abstract
DOI: 10.1158/1538-7445.sabcs23-po5-19-08
Authors: Heather McArthur, Jorge Henrique Santos Leal, Isaac Chan, Nisha Unni, Stephen Shiao, Joshua Gruber, Samira Syed, Namrata Peswani, Navid Sadeghi, Glenda Delgado, Dawn Klemow, Reva Basho, Meredith Carter, Mai Badran, Nasir Qureshi, Jessica Curtin, Joshua Weese, Stephanie Rice, Michelle Phillips, David Chan, Hugo Hool, Dorothy Park, Mary El-Masry, Philomena McAndrew, Swati Sikaria, Laura Spring, Aditya Bardia, Mourad Tighiouart, Farnaz Dadmanesh, Armando Giuliano, Katherine Sanchez, David Page
Institutions: The University of Texas Southwestern Medical Center, Cedars-Sinai Medical Center, Ellison Medical Institute, Harold C. Simmons Comprehensive Cancer Center, Oncotherapeutics (United States), Massachusetts General Hospital, New Mexico Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W4396587112
Cites:
Cited by:
Related to: 10